AKR1B10免疫组化在胰腺囊性病变手术切除与细针穿刺细胞学材料中的表达及非手术诊断潜力
研究评估AKR1B10免疫组化在胰腺囊性肿瘤手术切除标本和细针穿刺(FNA)细胞块中的表达,以寻找恶性潜能的生物标志物。结果显示AKR1B10在黏液性病变中高表达(46例中45例,98%),而在非黏液性病变(49例)中无染色。表明AKR1B10是黏液性胰腺囊性肿瘤的潜在恶性标志物,并可在细胞学FNA材料中检测,有望改善非手术诊断并指导手术切除决策。
要点
- AKR1B10在黏液性胰腺囊性肿瘤中高表达(98%),非黏液性病变无表达。
- AKR1B10染色可在FNA细胞块中完成,有望用于术前恶性潜能评估。
- 该标志物可能帮助筛选适合手术切除的胰腺囊性病变患者。
核心结论
- AKR1B10在黏液性胰腺囊性肿瘤中上调,是恶性潜能的 promising 生物标志物。
- AKR1B10免疫组化可在细胞学FNA材料中实施,有望改善非手术诊断。
研究设计与样本
- 回顾性分析手术切除标本和FNA细胞块的免疫组化表达。
- 纳入MCN(n=28)、IPMN(n=18)、囊性NET(n=20)、假性囊肿(n=13)和浆液性囊腺瘤(n=16)。
主要发现
- AKR1B10在46例黏液性病变中45例(98%)表达。
- 强染色(2+-3+/60%-100%染色)见于18例IPMN中的16例(89%)和28例MCN中的25例(90%)。
- 非黏液性病变(n=49)均无染色。
关键数值与推荐
- AKR1B10表达定义为免疫组化染色阳性。
- 强染色标准为2+-3+且60%-100%细胞染色。
临床怎么用
- 对胰腺囊性病变的FNA细胞块进行AKR1B10免疫组化染色,辅助鉴别黏液性与非黏液性病变。
- AKR1B10阳性提示黏液性肿瘤,可能具有恶性潜能,应考虑手术切除。
局限性
- 样本量有限,需进一步验证。
- 回顾性设计,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cystic pancreatic tumors account for 10% of cystic lesions in the pancreas. Evaluation focuses on identifying lesions that require surgical resection due to actual or potential malignancy. Cystic tumors with malignant potential include mucinous cystic neoplasms (MCNs), intraductal papillary mucinous neoplasms (IPMNs), and cystic neuroendocrine tumors (NETs). The sensitivity of endoscopic fine needle aspiration (FNA) to diagnose such lesions is low, and a more accurate marker of malignant potential is needed. Aldo-keto reductase 1B10 (AKR1B10) was originally found in human hepatocellular carcinoma. Since then, it has been identified in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia. Because there is difficulty in determining the malignant potential of cystic pancreatic tumors, we set out to examine the expression of AKR1B10 in these lesions as a potential biomarker of malignancy. AKR1B10 expression was analyzed in cell blocks from FNAs and surgical resection specimens using immunohistochemistry. We examined MCN (n=28), IPMN (n=18), and cystic NET (n=20) as well as nonmucinous cysts including pseudocysts (n=13) and serous cystadenomas (n=16). AKR1B10 expression was seen in 45 of 46 (98%) mucinous lesions evaluated. Strong staining (2+-3+/60%-100% staining) was seen in 16 of 18 (89%) IPMNs and 25 of 28 (90%) MCNs. No staining was seen in the nonmucinous lesions (n=49). In conclusion, AKR1B10 is upregulated in mucinous cystic pancreatic tumors, and this staining can be accomplished in cytology FNA material, making AKR1B10 a promising biomarker of malignant potential. Most importantly, this application could impact the clinical management of these patients by determining the best candidates for surgical resection.
引用
- Connor JP, Esbona K, Matkowskyj KA, et al. AKR1B10 expression by immunohistochemistry in surgical resections and fine needle aspiration cytology material in patients with cystic pancreatic lesions; potential for improved nonoperative diagnosis. Hum Pathol. 2017. PMID: 29079172. doi:10.1016/j.humpath.2017.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。